ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Copaxone® 40 mg/ml seringues préremplies:Teva Pharma AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
L03AX13 - Glatiramer AcetateATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L03 - Immunostimulants

Immunosuppressants, see L04A.

L03A - Immunostimulants

Levamisole, which also affects the immune response, is classified in P02CE.

L03AX - Other Immunostimulants
 

The DDD for tasonermin is based on single dose treatment.
The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).

L03AX13 - Glatiramer Acetate
Concentr.Adm.RouteNote
 P 
2025 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home